Story perspectives

Promising Treatment Boosts Progranulin Levels for Dementia

11/27/2025

30 7

Summary

Story summary

VES001 increased progranulin levels by more than 95% in early-stage trials for frontotemporal dementia conducted in the Netherlands and the United Kingdom.
The trials included participants at genetic risk for frontotemporal dementia.
No serious side effects were reported.
Anders Nykjær, Chief Scientific Officer of Vesper Bio, said the treatment could help prevent FTD development.
Further clinical trials are needed before the treatment is publicly available.

1 of 1

Story summary

VES001 increased progranulin levels by more than 95% in early-stage trials for frontotemporal dementia conducted in the Netherlands and the United Kingdom.
The trials included participants at genetic risk for frontotemporal dementia.
No serious side effects were reported.
Anders Nykjær, Chief Scientific Officer of Vesper Bio, said the treatment could help prevent FTD development.
Further clinical trials are needed before the treatment is publicly available.